Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned to offload the remainder of shares by striking a deal with its investors to exchange Bausch Health stock for Bausch + Lomb stock.

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.

Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International,

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.